Literature DB >> 9428617

Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression.

H G Zimmer1.   

Abstract

The effect of beta- and alpha-adrenergic stimulation on cardiovascular function and development of cardiac hypertrophy was studied in rats by measuring the heart weight/body weight and cardiac RNA/DNA ratios. Beta-receptor stimulation with isoproterenol over 3 days induced an increase in the biosynthesis of cardiac adenine nucleotides, myocardial protein synthesis, and the heart weight/body weight ratio. The isoproterenol-induced metabolic effects were prevented by simultaneous beta-adrenergic blockade with propranolol. Alpha-adrenergic stimulation with norfenephrine for 3 days induced an increase in heart rate, total peripheral resistance, the myocardial RNA/DNA, and left ventricular weight/body weight ratio. The calcium antagonist verapamil prevented the hemodynamic changes but did not influence the development of cardiac hypertrophy. The alpha-adrenergic blocker prazosin reversed the norfenephrine-induced functional changes and prevented cardiac hypertrophy. Norepinephrine was infused into isolated perfused working rat hearts to elucidate some molecular biological changes that precede the development of cardiac hypertrophy. It increased transiently and sequentially the mRNA of c-fos and c-myc. This enhancement occurred at about the same time as that induced by elevation of pre- and afterload but was more pronounced. These findings were compared with those obtained in other studies assessing the effects of catecholamines on proto-oncogene expression. Combination of norepinephrine with pre- and afterload elevation induced the c-fos mRNA signal to appear earlier, to be more pronounced, and to persist for a longer period of time. Similar results were obtained in regard to the c-myc mRNA. These findings indicate that the combination of two hypertrophy-inducing stimuli which may cause a higher degree of cardiac hypertrophy in vivo induce an earlier, more pronounced, and longer lasting expression of the proto-oncogenes c-fos and c-myc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428617     DOI: 10.1007/s001090050176

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  14 in total

1.  mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module.

Authors:  K L Dodge; S Khouangsathiene; M S Kapiloff; R Mouton; E V Hill; M D Houslay; L K Langeberg; J D Scott
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

2.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy.

Authors:  C J Friddle; T Koga; E M Rubin; J Bristow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

4.  Cardiomyocyte expression and cell-specific processing of procholecystokinin.

Authors:  Jens P Goetze; Anders H Johnsen; Caroline Kistorp; Finn Gustafsson; Camilla B Johnbeck; Jens F Rehfeld
Journal:  J Biol Chem       Date:  2015-01-27       Impact factor: 5.157

5.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.

Authors:  Robert Lukowski; Sergei D Rybalkin; Florian Loga; Veronika Leiss; Joseph A Beavo; Franz Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

6.  Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy.

Authors:  Julie A Wolfram; Edward J Lesnefsky; Brian D Hoit; Mark A Smith; Hyoung-Gon Lee
Journal:  Ther Adv Chronic Dis       Date:  2011-03-01       Impact factor: 5.091

7.  Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.

Authors:  C Pellieux; T Sauthier; A Domenighetti; D J Marsh; R D Palmiter; H R Brunner; T Pedrazzini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  Role of beta 1- and beta 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes.

Authors:  Klaus Pönicke; Ingrid Heinroth-Hoffmann; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

Review 9.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

10.  Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy.

Authors:  Yumei Feng; Chetan Hans; Elizabeth McIlwain; Kurt J Varner; Eric Lazartigues
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.